Ascribe Bioscience develops products that enable farmers to combat crop pathogens without negative impacts on the environment.
Ascribe Bioscience has raised $12.0M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
Ascribe Bioscience's investors include National Science Foundation, Cultivation Capital, The Yield Lab, Acre Venture Partners, Creative Destruction Lab (CDL).
Ascribe Bioscience is headquartered in Ithaca, United States.
Ascribe Bioscience develops products that enable farmers to combat crop pathogens without negative impacts on the environment.
Ascribe Bioscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ascribe Bioscience — Funding & Investors." VCBacked, October 14, 2025, https://www.vcbacked.co/company/ascribe-bioscience. Accessed October 22, 2026.
VCBacked. (2025). Ascribe Bioscience — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/ascribe-bioscience
{{cite web |title=Ascribe Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/ascribe-bioscience |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated